Revvity, Inc. (RVTY) Stock Price & How to Invest

Revvity runs two reporting segments of nearly identical size. Life Sciences sold ~$720.5 million in the first half of fiscal 2026 and covers two product lines: Life Sciences Solutions (~$601.0 million), meaning reagents, assays, labeling and detection chemistry, automation and high-content imaging systems such as the Opera Phenix platform, and Signals software (~$119.5 million), a scientific informatics suite sold on subscription to pharmaceutical R&D organizations. Diagnostics sold ~$720.3 million over the same period and also splits two ways: immunodiagnostics (~$416.6 million), largely the EUROIMMUN autoimmune, allergy and infectious-disease immunoassay franchise, and reproductive health (~$303.7 million), which is newborn screening, prenatal testing and related genomic services. Customers are pharmaceutical and biotech R&D groups, clinical and public-health laboratories, academia and governments across more than 160 countries, served by roughly 11,000 employees. Geography is spread wide rather than concentrated: in the June quarter the Americas produced ~$325.6 million, Europe ~$229.0 million and Asia ~$175.1 million. A large share of revenue is consumable or subscription in nature, since assays, reagents and screening kits get bought again every period, while instruments and software licenses carry the cyclical part of the business.

The investment picture turns on three things: whether Diagnostics keeps compounding, whether pharma instrument and software spending recovers, and how much of the GAAP earnings gap an owner is willing to look through. Revenue has been close to flat over three fiscal years, ~$2.751 billion in 2023, ~$2.755 billion in 2024 and ~$2.856 billion in 2025, so the equity story has been margin, buybacks and mix rather than volume. Adjusted operating margin ran 28.9% in the June quarter against a GAAP operating margin of 12.2%, and the wedge between them is ~$84.9 million of quarterly intangible amortization sitting on ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles, the accounting residue of the acquisition spree that built EUROIMMUN, BioLegend and the Signals portfolio. Management raised full-year guidance on August 4, 2026 to 4% to 5% pro forma organic growth and $5.30 to $5.40 of pro forma adjusted EPS. Guidance is now stated excluding the China immunodiagnostics business, which is under a signed agreement to be sold, so the guided revenue base and the reported revenue base are no longer the same thing.

The most immediate risk is that a chunk of 2026 profit does not repeat. Following the Supreme Court's February 20, 2026 ruling that the International Emergency Economic Powers Act does not authorize tariffs, Revvity applied through the Customs and Border Protection refund process for $20.2 million and had received $16.2 million by July 5, 2026. The company books these on receipt and has recorded no refund receivable, and the full $16.2 million landed in cost of revenue in a single quarter, worth roughly $0.11 of the $1.41 adjusted EPS and a good part of the 260 basis points of gross margin expansion. Second, the end market has not fully turned. Pharma and biotech sales declined mid-single digits including software in the quarter, academic and government budgets remain unsettled, and instruments are a deferrable purchase when customers are cautious. Third, the China divestiture is signed but not closed, with completion expected only by the end of 2027 and conditioned on regulatory approval, so Revvity carries the unit's declining results in the meantime while guiding without it. Fourth, the balance sheet is intangible-heavy: ~$6.61 billion of goodwill and ~$2.22 billion of net intangibles against ~$12.05 billion of total assets and ~$7.23 billion of equity, which leaves real impairment exposure if any acquired franchise underperforms. Fifth, restructuring is ongoing and disruptive, with severance actions in the first half of 2026 touching roughly 5% of the workforce and ~$46.2 million of charges recorded. Sixth, reproductive health revenue is tied to birth rates and to public-health screening budgets, both outside the company's control, and tuberculosis testing in the Americas is already a stated drag. Debt is ~$2.65 billion after the July repayment, with interest expense of ~$47.7 million in the half. Finally, the stock sits at the top of its 52-week range, which leaves little room for a guidance miss.

15 analysts publish price targets on RVTY, averaging $121.07 against a $124.75 price as of August 2026, or -2.9%. The published targets run from $100.00 to $145.00, a moderate spread, and the ratings split 6 buy, 11 hold, 0 sell. Over the last six months there have been 4 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RVTY forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Revvity, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Diagnostics is carrying the growth, and newborn screening is carrying Diagnostics. Diagnostics revenue reached ~$371.0 million in the quarter ended July 5, 2026, up from ~$354.4 million a year earlier, and grew 12% on a pro forma basis with 11% pro forma organic growth. The most optimistic published target, $145.00, assumes this works close to its best case.

The case against. The most immediate risk is that a chunk of 2026 profit does not repeat. The most pessimistic target, $100.00, is roughly what RVTY is worth if this bites instead.

Read the full bull and bear case on RVTY, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Revvity, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$2.912 billion for the twelve months to July 5, 2026, derived from ~$2.856 billion in fiscal 2025 plus first-half 2026 revenue of ~$1.441 billion less first-half 2025 revenue of ~$1.385 billion. Growth has been slow rather than absent: ~$2.751 billion in fiscal 2023, ~$2.755 billion in fiscal 2024 and ~$2.856 billion in fiscal 2025. June-quarter revenue was ~$729.7 million versus ~$720.3 million. Note that fiscal 2026 ends January 3, 2027 and contains 53 weeks, one more than fiscal 2025.
• GAAP earnings versus adjusted earnings: Trailing twelve-month net income is ~$237.6 million and trailing diluted EPS ~$2.08, down from $2.07 for full-year 2025 and $2.20 for 2024. Adjusted EPS from continuing operations was $1.41 in the June quarter against $1.18, and $2.47 for the half against $2.19. The bridge for the quarter is $0.76 of intangible amortization, $0.32 of restructuring, $0.05 of investment mark-to-market and $0.02 of purchase accounting, less $0.21 of tax. Full-year 2026 pro forma adjusted EPS is guided to $5.30 to $5.40, raised on August 4, 2026 from $5.20 to $5.30.
• Segment and product-line mix: First-half 2026 revenue splits almost evenly, Life Sciences ~$720.5 million and Diagnostics ~$720.3 million. Within Life Sciences: Life Sciences Solutions ~$601.0 million and Signals software ~$119.5 million. Within Diagnostics: immunodiagnostics ~$416.6 million and reproductive health ~$303.7 million. Segment adjusted operating margins in the June quarter were 31.1% for Life Sciences (down from 31.6%) and 30.4% for Diagnostics (up from 25.2%). Consolidated adjusted operating income was ~$211.0 million at a 28.9% margin, against GAAP operating income of ~$89.3 million at 12.2%. Corporate cost was ~$13.4 million in the quarter.
• Cash flow and balance sheet: Operating cash flow from continuing operations was ~$317.8 million in the first half of 2026 versus ~$268.4 million a year earlier, on capital expenditure of ~$30.8 million, and was ~$589.0 million for full-year 2025. Cash stood at ~$1.023 billion on July 5, 2026 against ~$3.222 billion of debt principal, of which the EUR 500.0 million 1.875% notes were repaid at maturity in July for ~$571.2 million. That leaves ~$2.65 billion outstanding across notes maturing 2028, 2029, two 2031 tranches and 2051, plus an undrawn $1.5 billion revolver running to January 2030. Goodwill is ~$6.61 billion, net intangibles ~$2.22 billion, equity ~$7.23 billion.
• Market pricing: The shares closed at ~$124.75 on August 21, 2026 against a 52-week range of ~$81.22 to ~$124.97, giving a market capitalization of ~$13.9 billion on ~111.6 million shares outstanding as of July 5, 2026. There is one class of common stock, with 300 million authorized. Trailing GAAP P/E is ~60x; against the midpoint of 2026 adjusted EPS guidance the multiple is ~23x. Price-to-sales is ~4.8x on trailing revenue. Enterprise value is ~$16.1 billion after netting ~$2.2 billion of net debt, which puts EV/sales near 5.5x and EV/adjusted EBITDA in the high teens against roughly $890 million of implied 2026 adjusted EBITDA.
• Dividend and buyback: The quarterly dividend is $0.07 a share, $0.28 annualized, for a yield of roughly 0.2% at the current price. Repurchases do the heavy lifting instead: ~$820.8 million in fiscal 2025 and ~$102.5 million in the first half of 2026, cutting weighted average diluted shares to ~111.7 million from ~118.9 million year over year. Research and development spending was ~$106.9 million in the half, flat against the prior year and about 7.4% of revenue.

The multiple depends entirely on which earnings line an owner treats as economic. A trailing GAAP P/E near 60x reflects ~$340 million a year of amortization on intangibles Revvity paid cash for in prior years; a forward multiple near 23x on guided adjusted EPS treats that amortization as sunk. Either way the stock is priced above the mid-teens multiples common in slow-growth diagnostics and below the premium attached to faster-compounding life-science tools names. Revenue growth of 4% to 5% organic, with margin and buyback doing the rest, is what the current price appears to assume.

Other names that sit close to RVTY: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get RVTY exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so RVTY sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RVTY fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

In August 2026 RVTY trades near $125, within a dollar of its 52-week high, on ~$2.91 billion of trailing revenue and company guidance of $5.30 to $5.40 in fiscal 2026 pro forma adjusted EPS. Trailing GAAP EPS is ~$2.08, and the difference is almost entirely purchase-accounting amortization, so the choice of earnings figure moves the multiple between roughly 23x and roughly 60x.

Whether RVTY is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RVTY a buy or a sell?, and where the stock could go from here in the RVTY stock forecast.

For income investors, whether RVTY pays a dividend and how the payout looks is covered in does RVTY pay a dividend? And to weigh RVTY against a peer, read the full side-by-side comparisons: RVTY vs TMO and RVTY vs DHR.